Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 11
Submit an article Journal homepage
1,474
Views
30
CrossRef citations to date
0
Altmetric
Vaccine Profile

Quadrivalent Ann Arbor strain live-attenuated influenza vaccine

Seth L Toback MedImmune, LLC, Gaithersburg, MD, USA; MedImmune, LLC, Gaithersburg, MD, USA
,
Myron J Levin University of Colorado Denver School of Medicine, Aurora, CO, USA; University of Colorado Denver School of Medicine, Aurora, CO, USA
,
Stan L Block Kentucky Pediatric and Adult Research, Bardstown, KY, USA; Kentucky Pediatric and Adult Research, Bardstown, KY, USA
,
Robert B Belshe Saint Louis University School of Medicine, Saint Louis, MO, USA; Saint Louis University School of Medicine, Saint Louis, MO, USA
,
Christopher S Ambrose MedImmune, LLC, Gaithersburg, MD, USA; MedImmune, LLC, Gaithersburg, MD, USA. [email protected]
&
Judith Falloon MedImmune, LLC, Gaithersburg, MD, USA; MedImmune, LLC, Gaithersburg, MD, USA
Pages 1293-1303 | Published online: 09 Jan 2014

References

  • Fiore AE, Uyeki TM, Broder K et al.; CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8), 1–62 (2010).
  • Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175(1), 59–68 (1990).
  • Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28(9), 2149–2156 (2010).
  • Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 8(1), 81–88 (2012).
  • Olson DR, Heffernan RT, Paladini M, Konty K, Weiss D, Mostashari F. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med. 4(8), e247 (2007).
  • Grant KA, Carville K, Fielding JE et al. High proportion of influenza B characterises the 2008 influenza season in Victoria. Commun. Dis. Intell. 33(3), 328–336 (2009).
  • Bettis R, Iacuzio D, Jung T, Fuchs R, Aultman R, Gyldmark M. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin. Drug Investig. 26(6), 329–340 (2006).
  • Chi CY, Wang SM, Lin CC et al. Clinical features of children infected with different strains of influenza B in southern Taiwan. Pediatr. Infect. Dis. J. 27(7), 640–645 (2008).
  • Daley AJ, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospitalized children. J. Paediatr. Child Health 36(4), 332–335 (2000).
  • Hite LK, Glezen WP, Demmler GJ, Munoz FM. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int. J. Infect. Dis. 11(1), 40–47 (2007).
  • Hu JJ, Kao CL, Lee PI et al. Clinical features of influenza A and B in children and association with myositis. J. Microbiol. Immunol. Infect. 37(2), 95–98 (2004).
  • Irving SA, Patel DC, Kieke BA et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza Other Respi. Viruses 6(1), 37–43 (2012).
  • McCullers JA, Hayden FG. Fatal influenza B infections: time to reexamine influenza research priorities. J. Infect. Dis. 205(6), 870–872 (2012).
  • Ng S, Cowling BJ, Fang VJ et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin. Infect. Dis. 50(5), 707–714 (2010).
  • Paddock CD, Liu L, Denison AM et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J. Infect. Dis. 205(6), 895–905 (2012).
  • Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin. Infect. Dis. 36(3), 299–305 (2003).
  • Principi N, Esposito S, Gasparini R, Marchisio P, Crovari P; Flu–Flu Study Group. Burden of influenza in healthy children and their households. Arch. Dis. Child. 89(11), 1002–1007 (2004).
  • Shen CF, Huang SC, Wang SM, Wang JR, Liu CC. Decreased leukocytes and other characteristics of laboratory findings of influenza virus infections in children. J. Microbiol. Immunol. Infect. 41(4), 294–300 (2008).
  • Esposito S, Cantarutti L, Molteni CG et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J. Infect. 62(5), 379–387 (2011).
  • Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 292(11), 1333–1340 (2004).
  • Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179–186 (2003).
  • Cox NJ, Subbarao K. Influenza. Lancet 354(9186), 1277–1282 (1999).
  • Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30(11), 1993–1998 (2012).
  • Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563–571 (2009).
  • Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 15(2), 295–323 (2002).
  • Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev. Med. Virol. 9(4), 237–244 (1999).
  • Aleksandrova GI. Use of the genetic recombination method for obtaining vaccinal strains of the influenza virus. Vopr. Virusol. 4, 387–395 (1977).
  • Tennis P, Toback SL, Andrews E, McQuay LJ, Ambrose CS. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 29(31), 4947–4952 (2011).
  • Baxter R, Toback SL, Sifakis F et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age. Vaccine 30(20), 3053–3060 (2012).
  • Baxter R, Toback SL, Sifakis F et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine 30(19), 2989–2998 (2012).
  • De Villiers PJ, Steele AD, Hiemstra LA et al.; LAIV Elderly Study Trial Network. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28(1), 228–234 (2009).
  • Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282(2), 137–144 (1999).
  • Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 30(5), 886–892 (2012).
  • Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2–17 years. Influenza Other Respi. Viruses 5(6), 389–397 (2011).
  • Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin. Infect. Dis. 39(7), 920–927 (2004).
  • Belshe RB, Edwards KM, Vesikari T et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685–696 (2007).
  • FluMist® (influenza vaccine live, intranasal) prescribing information. MedImmune, MD, USA (2012).
  • Smith H, Sweet C. Lessons for human influenza from pathogenicity studies with ferrets. Rev. Infect. Dis. 10(1), 56–75 (1988).
  • Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev. Vaccines 10(8), 1131–1141 (2011).
  • Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 29(50), 9391–9397 (2011).
  • Block SL, Falloon J, Hirschfield JA et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 31(7), 745–751 (2012).
  • Griffin MR, Walker FJ, Iwane MK, Weinberg GA, Staat MA, Erdman DD; New Vaccine Surveillance Network Study Group. Epidemiology of respiratory infections in young children: insights from the new vaccine surveillance network. Pediatr. Infect. Dis. J. 23(Suppl. 11), S188–S192 (2004).
  • Mallory RM, Malkin E, Ambrose CS et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 5(10), e13755 (2010).
  • Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169(1), 68–76 (1994).
  • Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18(9–10), 899–906 (1999).
  • Boyce TG, Gruber WC, Coleman-Dockery SD et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 18(1–2), 82–88 (1999).
  • Forrest BD, Pride MW, Dunning AJ et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 15(7), 1042–1053 (2008).
  • Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405–1412 (1998).
  • Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181(3), 1133–1137 (2000).
  • Tam JS, Capeding MR, Lum LC et al.; Pan-Asian CAIV-T Pediatric Efficacy Trial Network. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr. Infect. Dis. J. 26(7), 619–628 (2007).
  • Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age. Vaccine 26(38), 4940–4946 (2008).
  • King JC Jr, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177(5), 1394–1397 (1998).
  • Zangwill KM, Droge J, Mendelman P et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr. Infect. Dis. J. 20(8), 740–746 (2001).
  • Lee MS, Mahmood K, Adhikary L et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 23(9), 852–856 (2004).
  • Breiman RF, Brooks WA, Goswami D et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 27(40), 5472–5479 (2009).
  • Bracco Neto H, Farhat CK, Tregnaghi MW et al.; D153-P504 LAIV Study Group. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr. Infect. Dis. J. 28(5), 365–371 (2009).
  • Nolan T, Lee MS, Cordova JM et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21(11–12), 1224–1231 (2003).
  • Block SL, Reisinger KS, Hultquist M, Walker RE; CAIV-T Study Group. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob. Agents Chemother. 51(11), 4001–4008 (2007).
  • Nolan T, Bernstein DI, Block SL et al.; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 121(3), 508–516 (2008).
  • Glezen P. Influenza viruses. In: Influenza Viruses. Feigin RD, Cherry JD, Demmler GJ, Kalpan SL (Eds). Saunders, PA, USA, 2395–2413 (2009).
  • Stuart-Harris CH, Schild GC, Oxford JS. Influenza, The Viruses and the Disease. Edward Arnold, London, UK (1985).
  • Collin N, de Radiguès X; WHO H1N1 Vaccine Task Force. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 27(38), 5184–5186 (2009).
  • Berman-Gorvine M. Quadrivalent FluMist clears FDA but won’t be on the market until 2013. The Pink Sheet 74(11), #00120312005 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.